1. Home
  2. LQDA vs DFIN Comparison

LQDA vs DFIN Comparison

Compare LQDA & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • DFIN
  • Stock Information
  • Founded
  • LQDA 2004
  • DFIN 1983
  • Country
  • LQDA United States
  • DFIN United States
  • Employees
  • LQDA N/A
  • DFIN N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • DFIN Other Consumer Services
  • Sector
  • LQDA Health Care
  • DFIN Consumer Discretionary
  • Exchange
  • LQDA Nasdaq
  • DFIN Nasdaq
  • Market Cap
  • LQDA 1.2B
  • DFIN 1.2B
  • IPO Year
  • LQDA 2018
  • DFIN N/A
  • Fundamental
  • Price
  • LQDA $12.21
  • DFIN $63.60
  • Analyst Decision
  • LQDA Strong Buy
  • DFIN Strong Buy
  • Analyst Count
  • LQDA 9
  • DFIN 3
  • Target Price
  • LQDA $27.67
  • DFIN $68.67
  • AVG Volume (30 Days)
  • LQDA 2.7M
  • DFIN 257.9K
  • Earning Date
  • LQDA 08-06-2025
  • DFIN 07-30-2025
  • Dividend Yield
  • LQDA N/A
  • DFIN N/A
  • EPS Growth
  • LQDA N/A
  • DFIN N/A
  • EPS
  • LQDA N/A
  • DFIN 3.01
  • Revenue
  • LQDA $14,144,000.00
  • DFIN $779,600,000.00
  • Revenue This Year
  • LQDA $185.38
  • DFIN $1.99
  • Revenue Next Year
  • LQDA $350.95
  • DFIN $4.64
  • P/E Ratio
  • LQDA N/A
  • DFIN $21.13
  • Revenue Growth
  • LQDA N/A
  • DFIN N/A
  • 52 Week Low
  • LQDA $8.26
  • DFIN $37.80
  • 52 Week High
  • LQDA $19.41
  • DFIN $71.01
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 35.27
  • DFIN 79.85
  • Support Level
  • LQDA $11.85
  • DFIN $61.12
  • Resistance Level
  • LQDA $13.83
  • DFIN $62.27
  • Average True Range (ATR)
  • LQDA 0.68
  • DFIN 1.21
  • MACD
  • LQDA -0.19
  • DFIN 0.09
  • Stochastic Oscillator
  • LQDA 12.23
  • DFIN 97.66

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

Share on Social Networks: